Haleon (HLN) Cash from Financing Activities (2021 - 2023)
Haleon (HLN) posted Cash from Financing Activities of -$841.5 million for Q4 2023, down 108.39% on a QoQ basis from $10.0 billion in Q4 2022, and down 108.39% year-over-year from $10.0 billion in Q4 2022.
Haleon (HLN) Cash from Financing Activities (2021 - 2023) Analysis & Trends
Haleon's Cash from Financing Activities history runs 3 years deep, the most recent figure standing at -$841.5 million for Q4 2023.
- Quarterly Cash from Financing Activities fell 108.39% year-over-year to -$841.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $18.7 billion (changed N/A YoY) and the FY2025 annual result came in at -$4.1 billion, down 110.93% from the prior year.
- Cash from Financing Activities was -$841.5 million for Q4 2023 at Haleon, down from $10.0 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $10.5 billion in Q3 2022 and bottomed at -$965.2 million in Q4 2021.
- A 3-year average of $4.7 billion and a median of $4.6 billion in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 1138.55% — and 2023, when it sank 108.39%.
- Haleon's Cash from Financing Activities stood at -$965.2 million in 2021, then jumped by 1138.55% to $10.0 billion in 2022, then sank by 108.39% to -$841.5 million in 2023.
- Business Quant data shows HLN's Cash from Financing Activities at -$841.5 million in Q4 2023, $10.0 billion in Q4 2022, and $10.5 billion in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -841.50 Mn |
| Dec 31, 2023 | -841.50 Mn |
| Dec 31, 2022 | 10.02 Bn |
| Dec 31, 2022 | 10.02 Bn |
| Sep 20, 2022 | 10.52 Bn |
| Sep 20, 2022 | 10.52 Bn |
| Dec 31, 2021 | -965.18 Mn |
| Dec 31, 2021 | -965.18 Mn |